JP2019527706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527706A5 JP2019527706A5 JP2019506349A JP2019506349A JP2019527706A5 JP 2019527706 A5 JP2019527706 A5 JP 2019527706A5 JP 2019506349 A JP2019506349 A JP 2019506349A JP 2019506349 A JP2019506349 A JP 2019506349A JP 2019527706 A5 JP2019527706 A5 JP 2019527706A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- protein
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 235000018102 proteins Nutrition 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 239000002246 antineoplastic agent Substances 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000003839 Human Proteins Human genes 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000000270 basal cell Anatomy 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 208000011581 secondary neoplasm Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374621P | 2016-08-12 | 2016-08-12 | |
| US62/374,621 | 2016-08-12 | ||
| PCT/EP2017/070513 WO2018029367A1 (en) | 2016-08-12 | 2017-08-11 | Combination therapy for cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527706A JP2019527706A (ja) | 2019-10-03 |
| JP2019527706A5 true JP2019527706A5 (OSRAM) | 2020-09-24 |
| JP7573365B2 JP7573365B2 (ja) | 2024-10-25 |
Family
ID=59686928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019506349A Active JP7573365B2 (ja) | 2016-08-12 | 2017-08-11 | 癌の併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20180118832A1 (OSRAM) |
| EP (1) | EP3497130B1 (OSRAM) |
| JP (1) | JP7573365B2 (OSRAM) |
| KR (3) | KR20230125859A (OSRAM) |
| CN (1) | CN109641963A (OSRAM) |
| AU (2) | AU2017310027A1 (OSRAM) |
| BR (1) | BR112019001818A2 (OSRAM) |
| CA (1) | CA3031168A1 (OSRAM) |
| CL (1) | CL2019000277A1 (OSRAM) |
| ES (1) | ES2905663T3 (OSRAM) |
| IL (1) | IL264730B2 (OSRAM) |
| MX (1) | MX2019001503A (OSRAM) |
| PH (1) | PH12019500270A1 (OSRAM) |
| RU (1) | RU2019106663A (OSRAM) |
| SG (1) | SG11201901126UA (OSRAM) |
| WO (1) | WO2018029367A1 (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105658672A (zh) | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
| CN116327952A (zh) | 2015-08-04 | 2023-06-27 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| DK3628049T3 (da) | 2017-05-04 | 2023-08-14 | Acceleron Pharma Inc | Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf |
| CA3094500A1 (en) * | 2018-03-23 | 2019-09-26 | The University Of Western Australia | Method for immunotherapy drug treatment |
| WO2019211489A1 (en) * | 2018-05-04 | 2019-11-07 | Merck Patent Gmbh | COMBINED INHIBITION OF PD-1/PD-L1, TGFβ AND DNA-PK FOR THE TREATMENT OF CANCER |
| WO2019222252A1 (en) * | 2018-05-15 | 2019-11-21 | Merck Patent Gmbh | Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects |
| EP3806842A4 (en) * | 2018-06-13 | 2022-03-16 | Merck Patent GmbH | Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment |
| TW202019405A (zh) * | 2018-07-02 | 2020-06-01 | 德商馬克專利公司 | 用於治療晚期非小細胞肺癌之標靶性TGF-β抑制之組合療法 |
| US11535669B2 (en) * | 2018-07-09 | 2022-12-27 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| JP2022509156A (ja) * | 2018-11-30 | 2022-01-20 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 |
| EA202192130A1 (ru) | 2019-01-30 | 2021-12-28 | Сколар Рок, Инк. | Специфичные к ltbp-комплексу ингибиторы tgf и их применение |
| EP3693974A1 (en) * | 2019-02-07 | 2020-08-12 | Koninklijke Philips N.V. | Identifying responsiveness to radio-immuno combination therapy |
| US12325748B2 (en) | 2019-06-10 | 2025-06-10 | Shandong Boan Biotechnology Co., Ltd. | Bifunctional fusion protein against PDL1 and TGFβ and use thereof |
| WO2020263312A1 (en) * | 2019-06-28 | 2020-12-30 | Gensun Biopharma, Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
| CN112442132A (zh) * | 2019-09-05 | 2021-03-05 | 复旦大学 | 靶向肿瘤的重组双功能融合蛋白及其应用 |
| CA3151030A1 (en) * | 2019-09-12 | 2021-04-01 | David M. Evans | Co-delivery of tgf-.beta. sirna and pdl1 sirna to treat cancer |
| CN112574314A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 一种融合蛋白及其应用 |
| JP7495489B2 (ja) | 2019-10-21 | 2024-06-04 | ナンチン リーズ バイオラブス カンパニー，リミティド | ＰＤ－１およびＴＧＦβを標的化する組換えタンパク質 |
| IL292613A (en) * | 2019-11-01 | 2022-07-01 | Ares Trading Sa | Combined inhibition of pd-1, tgfβ and atm together with radiotherapy for the treatment of cancer |
| BR112022008295A2 (pt) | 2019-11-05 | 2022-07-26 | Merck Patent Gmbh | Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer |
| WO2021115456A1 (en) * | 2019-12-11 | 2021-06-17 | Wuxi Biologics (Shanghai) Co., Ltd. | BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFβ |
| EP3838260A1 (en) | 2019-12-20 | 2021-06-23 | Ares Trading S.A. | Igg:tgf rii fusion protein composition |
| CA3161504A1 (en) | 2019-12-20 | 2021-06-24 | Chiara IORIO | Igg:tgf.beta.rii fusion protein composition |
| CN115190812A (zh) | 2020-01-11 | 2022-10-14 | 供石公司 | TGFβ抑制剂及其用途 |
| JP2023511255A (ja) | 2020-01-11 | 2023-03-17 | スカラー ロック インコーポレイテッド | ＴＧＦ－β阻害剤及びその使用 |
| CN115175942B (zh) * | 2020-02-25 | 2025-05-30 | 上海药明生物技术有限公司 | 一种双功能融合蛋白及其用途 |
| AU2021256925A1 (en) * | 2020-04-14 | 2022-11-03 | Ares Trading S.A. | Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| WO2022011256A1 (en) | 2020-07-10 | 2022-01-13 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| JP7766672B2 (ja) * | 2020-07-24 | 2025-11-10 | ▲邁▼威（上海）生物科技股▲フン▼有限公司 | ＴＧＦ－β ＲＩＩ突然変異体及びその融合タンパク質 |
| CN116323657B (zh) * | 2020-09-24 | 2023-12-08 | 上海齐鲁制药研究中心有限公司 | 同时靶向PD-L1和TGFβ的双功能分子及其医药用途 |
| WO2022090529A1 (en) | 2020-11-02 | 2022-05-05 | Ares Trading S.A. | Combination treatment of cancer |
| CA3196557A1 (en) | 2020-11-02 | 2022-05-05 | Ada SALA-HOJMAN | Combination treatment of cancer |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| AU2022270880A1 (en) | 2021-05-03 | 2023-09-28 | Merck Patent Gmbh | Her2 targeting fc antigen binding fragment-drug conjugates |
| AU2022280341A1 (en) | 2021-05-25 | 2024-01-04 | Merck Patent Gmbh | Egfr targeting fc antigen binding fragment-drug conjugates |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| WO2022258622A1 (en) | 2021-06-07 | 2022-12-15 | Ares Trading S.A. | Combination treatment of cancer |
| GB202215997D0 (en) * | 2022-10-28 | 2022-12-14 | Io Biotech Aps | Therapy |
| KR20250133913A (ko) | 2023-01-09 | 2025-09-09 | 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 | TGFβ1 결합 분자, GARP-TGFβ1 결합 분자 및 이의 의학적 용도 |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE336514T1 (de) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
| BR0207854A (pt) | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2785375B1 (en) * | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| EP4219536A3 (en) * | 2012-04-30 | 2023-08-23 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| EP2855528B1 (en) * | 2012-05-31 | 2019-06-19 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| SG11201606577YA (en) * | 2014-02-10 | 2016-09-29 | Merck Patent Gmbh | TARGETED TGFβ INHIBITION |
-
2017
- 2017-08-11 AU AU2017310027A patent/AU2017310027A1/en not_active Abandoned
- 2017-08-11 CN CN201780049391.8A patent/CN109641963A/zh active Pending
- 2017-08-11 IL IL264730A patent/IL264730B2/en unknown
- 2017-08-11 RU RU2019106663A patent/RU2019106663A/ru unknown
- 2017-08-11 KR KR1020237028359A patent/KR20230125859A/ko not_active Ceased
- 2017-08-11 EP EP17755458.1A patent/EP3497130B1/en active Active
- 2017-08-11 ES ES17755458T patent/ES2905663T3/es active Active
- 2017-08-11 KR KR1020257005808A patent/KR20250028537A/ko active Pending
- 2017-08-11 WO PCT/EP2017/070513 patent/WO2018029367A1/en not_active Ceased
- 2017-08-11 CA CA3031168A patent/CA3031168A1/en active Pending
- 2017-08-11 KR KR1020197006703A patent/KR20190039200A/ko not_active Ceased
- 2017-08-11 JP JP2019506349A patent/JP7573365B2/ja active Active
- 2017-08-11 MX MX2019001503A patent/MX2019001503A/es unknown
- 2017-08-11 BR BR112019001818A patent/BR112019001818A2/pt unknown
- 2017-08-11 SG SG11201901126UA patent/SG11201901126UA/en unknown
- 2017-08-11 US US15/674,655 patent/US20180118832A1/en not_active Abandoned
-
2019
- 2019-02-01 CL CL2019000277A patent/CL2019000277A1/es unknown
- 2019-02-07 PH PH12019500270A patent/PH12019500270A1/en unknown
-
2021
- 2021-06-24 US US17/357,380 patent/US20220017621A1/en not_active Abandoned
-
2024
- 2024-09-06 AU AU2024219446A patent/AU2024219446A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527706A5 (OSRAM) | ||
| RU2019106663A (ru) | Комбинированная терапия рака | |
| JP2017506217A5 (OSRAM) | ||
| Bianco et al. | Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide | |
| JP2018508512A5 (OSRAM) | ||
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2020514290A5 (OSRAM) | ||
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| TWI599369B (zh) | 包含阿柏西普（ａｆｌｉｂｅｒｃｅｐｔ）、醛葉酸、５－氟尿嘧啶（５－ｆｕ）及伊立替康（ｉｒｉｎｏｔｅｃａｎ）（ｆｏｌｆｉｒｉ）之組合物 | |
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| IL278423B2 (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| JP2016527286A5 (OSRAM) | ||
| JP2016520082A5 (OSRAM) | ||
| EA202091514A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR | |
| JP2011103891A5 (OSRAM) | ||
| EP4434540A3 (en) | Humanized anti-il-1r3 antibodies | |
| EA201000127A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
| Kubicek et al. | Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies | |
| JP2020517658A5 (OSRAM) | ||
| Pirker et al. | Cetuximab in non-small-cell lung cancer | |
| RU2016112421A (ru) | Протиоопухолевое средство и усилитель противоопухолевого эффекта | |
| JP2018512402A5 (OSRAM) | ||
| JP2016504420A5 (OSRAM) | ||
| JP2019506392A5 (OSRAM) |